Use of belatacept as alternative graft vs host disease prophylaxis in pediatric allogeneic hematopoietic stem cell transplantation

Immunosuppressive prophylaxis is usually given to decrease the development of acute graft versus host disease (GvHD) after allogeneic hematopoietic stem cell transplantation (HSCT). Belatacept is a Cytotoxic T‐lymphocyte‐associated protein 4, blocking agent, an immunosuppressive agent used for organ rejection prevention in adult renal transplant recipients.

• Publication year

  2021

• Venue

  Pediatric Transplantation

• Publication date

  2021-05-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/petr.14041PMID 34014014
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• acute graft versus host disease

  condition, complication

  An early post-transplant complication that prophylactic immunosuppression aims to prevent.

  Aliases: acute GvHD, aGvHD

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAK (4715169a40) reviewimjlk (vdp8mqzes2) review
• belatacept

  drug, immunosuppressive agent

  An immunosuppressive CTLA-4-blocking agent discussed here as the candidate prophylaxis drug.

  Aliases: CTLA-4 blocking agent

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAK (4715169a40) reviewimjlk (vdp8mqzes2) review
• graft versus host disease prophylaxis

  prophylaxis, treatment

  Immunosuppressive preventive treatment intended to reduce the risk of graft versus host disease after transplantation.

  Aliases: GvHD prophylaxis

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAK (4715169a40) reviewimjlk (vdp8mqzes2) review
• immunosuppressive prophylaxis

  prophylaxis, therapy

  Preventive use of immune-suppressing medication after allogeneic transplantation.

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAK (4715169a40) reviewimjlk (vdp8mqzes2) review
• pediatric allogeneic hematopoietic stem cell transplantation

  transplantation, clinical setting

  Allogeneic stem cell transplantation performed in pediatric patients, which is the clinical setting addressed in the title.

  Aliases: pediatric allo-HSCT, allogeneic HSCT in children

  박진우 (dztg5apj7m) extractionB (s683577b42) reviewAK (4715169a40) reviewimjlk (vdp8mqzes2) review

• Abatacept is effective as GVHD prophylaxis in unrelated donor stem cell transplantation for children with severe sickle cell disease.

  2020cited by this paper
• Graft Versus Host Disease Prophylaxis With Abatacept Reduces Severe Acute Graft Versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant for Beta Thalassemia Major with Busulfan, Fludarabine, and Thiotepa.

  2020cited by this paper
• Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation.

  2020cited by this paper
• Influence of Mixed Chimerism on Outcome in Children With Anaemia After Haematopoietic Stem Cell Transplantation

  2019cited by this paper
• Belatacept in Solid Organ Transplant: Review of Current Literature Across Transplant Types

  2018cited by this paper
• Maintenance Belatacept-Based Immunosuppression in Lung Transplantation Recipients Who Failed Calcineurin Inhibitors

  2018cited by this paper
• Outcomes of matched sibling donor bone marrow transplantation in children using single‐agent calcineurin inhibitors as prophylaxis for graft versus host disease

  2018cited by this paper
• How I treat myelodysplastic syndromes of childhood.

  2018cited by this paper
• Late conversion from tacrolimus to a belatacept-based immuno-suppression regime in kidney transplant recipients improves renal function, acid-base derangement and mineral-bone metabolism

  2017cited by this paper
• Ten‐year outcomes in a randomized phase II study of kidney transplant recipients administered belatacept 4‐weekly or 8‐weekly

  2017cited by this paper
• Mixed T Cell Chimerism After Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia Using an Alemtuzumab-Containing Regimen Is Shaped by Persistence of Recipient CD8 T Cells

  2017cited by this paper
• Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long‐Term Renal Allograft Function

  2017cited by this paper
• Effect of an Early Switch to Belatacept Among Calcineurin Inhibitor–Intolerant Graft Recipients of Kidneys From Extended‐Criteria Donors

  2016cited by this paper
• Belatacept and Long-Term Outcomes in Kidney Transplantation.

  2016cited by this paper
• Belatacept and Eculizumab for Treatment of Calcineurin Inhibitor-induced Thrombotic Microangiopathy After Kidney Transplantation: Case Report.

  2016cited by this paper
• Belatacept and Long-Term Outcomes in Kidney Transplantation.

  2016cited by this paper
• Belatacept: Is There BENEFIT for Liver Transplantation Too?

  2014cited by this paper
• Long‐Term Belatacept Exposure Maintains Efficacy and Safety at 5 Years: Results From the Long‐Term Extension of the BENEFIT Study

  2013cited by this paper
• Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients

  2013cited by this paper
• Use of Belatacept as Alternative Immunosuppression in Three Renal Transplant Patients with De Novo Drug-Induced Thrombotic Microangiopathy

  2013cited by this paper
• In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial.

  2013cited by this paper
• Allogeneic stem cell transplantation using alemtuzumab-containing regimens in severe aplastic anemia

  2013cited by this paper
• How I manage aplastic anaemia in children

  2012cited by this paper
• Summary of the US FDA Approval of Belatacept

  2012cited by this paper
• A Phase III Study of Belatacept Versus Cyclosporine in Kidney Transplants from Extended Criteria Donors (BENEFIT‐EXT Study)

  2010cited by this paper
• Graft-versus-host disease.

  2009cited by this paper
• Belatacept as Maintenance Immunosuppression for Postrenal Transplant de novo Drug‐Induced Thrombotic Microangiopathy

  2009cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• Rational Development of LEA29Y (belatacept), a High‐Affinity Variant of CTLA4‐Ig with Potent Immunosuppressive Properties

  2005cited by this paper
• Costimulation blockade with belatacept in renal transplantation.

  2005cited by this paper
• Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children

  2000cited by this paper

• A Difficult Case of Calcineurin Inhibitor Neurotoxicity Post-Haploidentical HCT With a Successful Novel Solution: Cytotoxic T-Lymphocyte-Associated Protein 4-Immunoglobulin Blockade for GVHD Prophylaxis

  2024cites this paper
• Reeling in complement in transplant‐associated thrombotic microangiopathy: You're going to need a bigger boat

  2023cites this paper
• T-lymphocyte depleted transplants for inborn errors of immunity

  2023cites this paper
• Belatacept/mycophenolate-mofetil/sirolimus

  2022cites this paper